InternationalUSRemember you can easily switch between MIP US and MIP International at any time

India Supreme Court: Novartis's Glivec patent not novel

Peter Leung, Hong Kong

The India Supreme Court has upheld the Intellectual Property Appellate Board's (IPAB) denial of Novartis's patent application for anti-cancer drug Glivec

Domestic generic manufacturers Ranbaxy and Cipla brought the opposition, with both represented by Singh & Singh. Anand & Anand acted for Novartis. You can read the Court's ruling here.

The comptroller of patents rejected the Glivec application for lack of novelty. Specifically...

Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

More from the Managing IP blog

null null null



May / June 2019

From trademarks to trade secrets: in-house tips on brand protection in China

Despite the well-known struggles in protecting trademarks and trade secrets in China, there are some tried-and-tested strategies to employ, as Karry Lai and Ellie Mertens hear from in-house counsel at a range of domestic and international companies

Most read articles